Will Tesla Stock Go Up In 2026?
EV giant Tesla (NASDAQ:TSLA) has, somewhat surprisingly, undershot the broader…
Sell
39
PCRX.V Quote, Financials, Valuation and Earnings
Last price:
$0.42
Seasonality move
:
95.83%
Day range:
$0.41 - $0.42
52-week range:
$0.40 - $0.66
Dividend yield:
0%
P/E ratio:
280.00x
P/S ratio:
2.85x
P/B ratio:
1.67x
Volume:
106.1K
Avg. volume:
219K
1-year change:
-31.15%
Market cap:
$50.1M
Revenue:
$5.8M
EPS (TTM):
$0.00
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PCRX.V
PharmaCorp Rx, Inc.
|
-- | -- | -- | -- | -- |
|
COV.V
Covalon Technologies Ltd.
|
$10.5M | -$0.04 | 9.42% | -6.98% | $2.90 |
|
HITI.V
High Tide, Inc.
|
$158.9M | -$0.01 | 25.2% | -97.56% | $7.75 |
|
IWIN.CX
Irwin Naturals, Inc.
|
-- | -- | -- | -- | -- |
|
KO.H.V
Kiaro Holdings
|
-- | -- | -- | -- | -- |
|
PKB.CX
PeakBirch Commerce, Inc.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PCRX.V
PharmaCorp Rx, Inc.
|
$0.42 | -- | $50.1M | 280.00x | $0.00 | 0% | 2.85x |
|
COV.V
Covalon Technologies Ltd.
|
$1.80 | $2.90 | $49.4M | 24.39x | $0.15 | 0% | 1.53x |
|
HITI.V
High Tide, Inc.
|
$3.74 | $7.75 | $325.8M | -- | $0.00 | 0% | 0.54x |
|
IWIN.CX
Irwin Naturals, Inc.
|
$0.30 | -- | $1M | -- | $0.00 | 0% | 0.01x |
|
KO.H.V
Kiaro Holdings
|
$0.0050 | -- | $184.1K | -- | $0.00 | 0% | 0.00x |
|
PKB.CX
PeakBirch Commerce, Inc.
|
$0.03 | -- | $249.8K | -- | $0.00 | 0% | 0.12x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PCRX.V
PharmaCorp Rx, Inc.
|
12.59% | 0.009 | 7.72% | 1.74x |
|
COV.V
Covalon Technologies Ltd.
|
6.83% | 0.762 | 3.91% | 6.16x |
|
HITI.V
High Tide, Inc.
|
36.24% | 2.359 | 32.33% | 1.22x |
|
IWIN.CX
Irwin Naturals, Inc.
|
-- | 0.000 | -- | -- |
|
KO.H.V
Kiaro Holdings
|
-- | 2.909 | -- | -- |
|
PKB.CX
PeakBirch Commerce, Inc.
|
-- | 0.000 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PCRX.V
PharmaCorp Rx, Inc.
|
$403.2K | -$498.8K | 0.57% | 0.6% | -10.39% | $537.5K |
|
COV.V
Covalon Technologies Ltd.
|
$4.2M | $245.8K | 6.62% | 6.87% | 2.83% | -$847.4K |
|
HITI.V
High Tide, Inc.
|
$14.9M | $5.4M | -4.42% | -6.56% | 3.6% | $8.4M |
|
IWIN.CX
Irwin Naturals, Inc.
|
-- | -- | -- | -- | -- | -- |
|
KO.H.V
Kiaro Holdings
|
-- | -- | -- | -- | -- | -- |
|
PKB.CX
PeakBirch Commerce, Inc.
|
-- | -- | -- | -- | -- | -- |
PharmaCorp Rx, Inc. vs. Competitors
-
Which has Higher Returns PCRX.V or COV.V?
Covalon Technologies Ltd. has a net margin of -8.52% compared to PharmaCorp Rx, Inc.'s net margin of 4.12%. PharmaCorp Rx, Inc.'s return on equity of 0.6% beat Covalon Technologies Ltd.'s return on equity of 6.87%.
Company Gross Margin Earnings Per Share Invested Capital PCRX.VPharmaCorp Rx, Inc.8.4% -$0.00 $34.5M COV.VCovalon Technologies Ltd.48.76% $0.01 $33M -
What do Analysts Say About PCRX.V or COV.V?
PharmaCorp Rx, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Covalon Technologies Ltd. has an analysts' consensus of $2.90 which suggests that it could grow by 61.11%. Given that Covalon Technologies Ltd. has higher upside potential than PharmaCorp Rx, Inc., analysts believe Covalon Technologies Ltd. is more attractive than PharmaCorp Rx, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PCRX.VPharmaCorp Rx, Inc.0 0 0 COV.VCovalon Technologies Ltd.1 0 0 -
Is PCRX.V or COV.V More Risky?
PharmaCorp Rx, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Covalon Technologies Ltd. has a beta of -0.206, suggesting its less volatile than the S&P 500 by 120.585%.
-
Which is a Better Dividend Stock PCRX.V or COV.V?
PharmaCorp Rx, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Covalon Technologies Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.15 per share. PharmaCorp Rx, Inc. pays -- of its earnings as a dividend. Covalon Technologies Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PCRX.V or COV.V?
PharmaCorp Rx, Inc. quarterly revenues are $4.8M, which are smaller than Covalon Technologies Ltd. quarterly revenues of $8.7M. PharmaCorp Rx, Inc.'s net income of -$409.2K is lower than Covalon Technologies Ltd.'s net income of $358.3K. Notably, PharmaCorp Rx, Inc.'s price-to-earnings ratio is 280.00x while Covalon Technologies Ltd.'s PE ratio is 24.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PharmaCorp Rx, Inc. is 2.85x versus 1.53x for Covalon Technologies Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PCRX.VPharmaCorp Rx, Inc.2.85x 280.00x $4.8M -$409.2K COV.VCovalon Technologies Ltd.1.53x 24.39x $8.7M $358.3K
-
Which has Higher Returns PCRX.V or HITI.V?
High Tide, Inc. has a net margin of -8.52% compared to PharmaCorp Rx, Inc.'s net margin of 0.56%. PharmaCorp Rx, Inc.'s return on equity of 0.6% beat High Tide, Inc.'s return on equity of -6.56%.
Company Gross Margin Earnings Per Share Invested Capital PCRX.VPharmaCorp Rx, Inc.8.4% -$0.00 $34.5M HITI.VHigh Tide, Inc.9.95% $0.01 $223.9M -
What do Analysts Say About PCRX.V or HITI.V?
PharmaCorp Rx, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand High Tide, Inc. has an analysts' consensus of $7.75 which suggests that it could grow by 107.22%. Given that High Tide, Inc. has higher upside potential than PharmaCorp Rx, Inc., analysts believe High Tide, Inc. is more attractive than PharmaCorp Rx, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PCRX.VPharmaCorp Rx, Inc.0 0 0 HITI.VHigh Tide, Inc.6 0 0 -
Is PCRX.V or HITI.V More Risky?
PharmaCorp Rx, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison High Tide, Inc. has a beta of 0.952, suggesting its less volatile than the S&P 500 by 4.811%.
-
Which is a Better Dividend Stock PCRX.V or HITI.V?
PharmaCorp Rx, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. High Tide, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PharmaCorp Rx, Inc. pays -- of its earnings as a dividend. High Tide, Inc. pays out 5.25% of its earnings as a dividend. High Tide, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios PCRX.V or HITI.V?
PharmaCorp Rx, Inc. quarterly revenues are $4.8M, which are smaller than High Tide, Inc. quarterly revenues of $149.7M. PharmaCorp Rx, Inc.'s net income of -$409.2K is lower than High Tide, Inc.'s net income of $832K. Notably, PharmaCorp Rx, Inc.'s price-to-earnings ratio is 280.00x while High Tide, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PharmaCorp Rx, Inc. is 2.85x versus 0.54x for High Tide, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PCRX.VPharmaCorp Rx, Inc.2.85x 280.00x $4.8M -$409.2K HITI.VHigh Tide, Inc.0.54x -- $149.7M $832K
-
Which has Higher Returns PCRX.V or IWIN.CX?
Irwin Naturals, Inc. has a net margin of -8.52% compared to PharmaCorp Rx, Inc.'s net margin of --. PharmaCorp Rx, Inc.'s return on equity of 0.6% beat Irwin Naturals, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PCRX.VPharmaCorp Rx, Inc.8.4% -$0.00 $34.5M IWIN.CXIrwin Naturals, Inc.-- -- -- -
What do Analysts Say About PCRX.V or IWIN.CX?
PharmaCorp Rx, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Irwin Naturals, Inc. has an analysts' consensus of -- which suggests that it could grow by 2582.67%. Given that Irwin Naturals, Inc. has higher upside potential than PharmaCorp Rx, Inc., analysts believe Irwin Naturals, Inc. is more attractive than PharmaCorp Rx, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PCRX.VPharmaCorp Rx, Inc.0 0 0 IWIN.CXIrwin Naturals, Inc.0 0 0 -
Is PCRX.V or IWIN.CX More Risky?
PharmaCorp Rx, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Irwin Naturals, Inc. has a beta of -0.139, suggesting its less volatile than the S&P 500 by 113.937%.
-
Which is a Better Dividend Stock PCRX.V or IWIN.CX?
PharmaCorp Rx, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Irwin Naturals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PharmaCorp Rx, Inc. pays -- of its earnings as a dividend. Irwin Naturals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PCRX.V or IWIN.CX?
PharmaCorp Rx, Inc. quarterly revenues are $4.8M, which are larger than Irwin Naturals, Inc. quarterly revenues of --. PharmaCorp Rx, Inc.'s net income of -$409.2K is higher than Irwin Naturals, Inc.'s net income of --. Notably, PharmaCorp Rx, Inc.'s price-to-earnings ratio is 280.00x while Irwin Naturals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PharmaCorp Rx, Inc. is 2.85x versus 0.01x for Irwin Naturals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PCRX.VPharmaCorp Rx, Inc.2.85x 280.00x $4.8M -$409.2K IWIN.CXIrwin Naturals, Inc.0.01x -- -- --
-
Which has Higher Returns PCRX.V or KO.H.V?
Kiaro Holdings has a net margin of -8.52% compared to PharmaCorp Rx, Inc.'s net margin of --. PharmaCorp Rx, Inc.'s return on equity of 0.6% beat Kiaro Holdings's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PCRX.VPharmaCorp Rx, Inc.8.4% -$0.00 $34.5M KO.H.VKiaro Holdings-- -- -- -
What do Analysts Say About PCRX.V or KO.H.V?
PharmaCorp Rx, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Kiaro Holdings has an analysts' consensus of -- which suggests that it could grow by 41900%. Given that Kiaro Holdings has higher upside potential than PharmaCorp Rx, Inc., analysts believe Kiaro Holdings is more attractive than PharmaCorp Rx, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PCRX.VPharmaCorp Rx, Inc.0 0 0 KO.H.VKiaro Holdings0 0 0 -
Is PCRX.V or KO.H.V More Risky?
PharmaCorp Rx, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Kiaro Holdings has a beta of 0.243, suggesting its less volatile than the S&P 500 by 75.658%.
-
Which is a Better Dividend Stock PCRX.V or KO.H.V?
PharmaCorp Rx, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kiaro Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PharmaCorp Rx, Inc. pays -- of its earnings as a dividend. Kiaro Holdings pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PCRX.V or KO.H.V?
PharmaCorp Rx, Inc. quarterly revenues are $4.8M, which are larger than Kiaro Holdings quarterly revenues of --. PharmaCorp Rx, Inc.'s net income of -$409.2K is higher than Kiaro Holdings's net income of --. Notably, PharmaCorp Rx, Inc.'s price-to-earnings ratio is 280.00x while Kiaro Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PharmaCorp Rx, Inc. is 2.85x versus 0.00x for Kiaro Holdings. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PCRX.VPharmaCorp Rx, Inc.2.85x 280.00x $4.8M -$409.2K KO.H.VKiaro Holdings0.00x -- -- --
-
Which has Higher Returns PCRX.V or PKB.CX?
PeakBirch Commerce, Inc. has a net margin of -8.52% compared to PharmaCorp Rx, Inc.'s net margin of --. PharmaCorp Rx, Inc.'s return on equity of 0.6% beat PeakBirch Commerce, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PCRX.VPharmaCorp Rx, Inc.8.4% -$0.00 $34.5M PKB.CXPeakBirch Commerce, Inc.-- -- -- -
What do Analysts Say About PCRX.V or PKB.CX?
PharmaCorp Rx, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand PeakBirch Commerce, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that PharmaCorp Rx, Inc. has higher upside potential than PeakBirch Commerce, Inc., analysts believe PharmaCorp Rx, Inc. is more attractive than PeakBirch Commerce, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PCRX.VPharmaCorp Rx, Inc.0 0 0 PKB.CXPeakBirch Commerce, Inc.0 0 0 -
Is PCRX.V or PKB.CX More Risky?
PharmaCorp Rx, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison PeakBirch Commerce, Inc. has a beta of -0.522, suggesting its less volatile than the S&P 500 by 152.22%.
-
Which is a Better Dividend Stock PCRX.V or PKB.CX?
PharmaCorp Rx, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PeakBirch Commerce, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PharmaCorp Rx, Inc. pays -- of its earnings as a dividend. PeakBirch Commerce, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PCRX.V or PKB.CX?
PharmaCorp Rx, Inc. quarterly revenues are $4.8M, which are larger than PeakBirch Commerce, Inc. quarterly revenues of --. PharmaCorp Rx, Inc.'s net income of -$409.2K is higher than PeakBirch Commerce, Inc.'s net income of --. Notably, PharmaCorp Rx, Inc.'s price-to-earnings ratio is 280.00x while PeakBirch Commerce, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PharmaCorp Rx, Inc. is 2.85x versus 0.12x for PeakBirch Commerce, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PCRX.VPharmaCorp Rx, Inc.2.85x 280.00x $4.8M -$409.2K PKB.CXPeakBirch Commerce, Inc.0.12x -- -- --
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Are the Best AI Power Stocks?
As the construction of AI infrastructure accelerates, the gap between…
Is IONQ The Best Quantum Stock to Buy?
Riding a wave of investor enthusiasm for the technology, quantum…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 60x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
71
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
39
SMX alert for Dec 16
SMX (Security Matters) Plc [SMX] is down 14.24% over the past day.
Sell
33
ZBIO alert for Dec 16
Zenas BioPharma, Inc. [ZBIO] is up 11.2% over the past day.
Sell
38
HUT alert for Dec 16
Hut 8 Corp. [HUT] is down 1.16% over the past day.
